Englander Institute for Precision Medicine

Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.

Dr. Omar Abdul-Rahman, a leading specialist in pediatric genetic medicine, has been named chief of the Division of Medical Genetics in the Department of Pediatrics at Weill Cornell Medicine and NewYork-Presbyterian Komansky Children’s Hospital, effective March 1.

An enzyme that defends human cells against viruses can help drive cancer evolution towards greater malignancy by causing myriad mutations in cancer cells.

An artificial intelligence algorithm can determine non-invasively, with about 70 percent accuracy, if an in vitro fertilized embryo has a normal or abnormal number of chromosomes.

A $20 million gift from Andrew H. ’71 and Ann R. Tisch will foster engagement and collaboration between Cornell Tech and Weill Cornell Medicine, catalyzing new discoveries at the intersection of health and technology.

Weill Cornell Medicine researchers have developed a computational method to map the architecture of human tissues in unprecedented detail.

Weill Cornell Medicine investigators have identified definitive biological links between African ancestry and disease processes that affect an aggressive cancer type called triple-negative breast cancer.

A collaboration between Weill Cornell Medicine scientists and other leaders in Alzheimer’s disease research has revealed widespread metabolic changes in the brains of individuals with Alzheimer’s disease. 

Artificial intelligence may soon help doctors diagnose and treat diseases, including cancer and depression, based on the sound of a patient’s voice, as 12 leading research institutions launch a landmark National Institutes of Health-funded academic project that may establish voice as a biomarker used in clinical care.

Weill Cornell Medicine and New York Genome Center researchers, in collaboration with Oxford Nanopore Technologies, have developed a new method to assess on a large scale the three-dimensional structure of the human genome, or how the genome folds.

Researchers at Weill Cornell Medicine and Memorial Sloan Kettering Cancer Center have identified a previously unrecognized form of hormone therapy-resistant prostate cancer, as well as a set of molecules that drive its growth. This discovery opens the door to the development of therapies that treat this specific disease.

Immunotherapy unleashes the power of the immune system to fight cancer. However, for some patients, immunotherapy doesn’t work, and new research may help explain why. 

Investigators at Weill Cornell Medicine have identified significant differences in the molecular characteristics of tumors from younger and older cancer patients across several cancer types.

A new protein variant underlies the ability of gastric cancers to resist an otherwise effective family of chemotherapy drugs, according to a study by a multidisciplinary team at Weill Cornell Medicine. The results suggest a treatment strategy that could improve the prognoses of many patients with cancer.

Dr. Virginia Pascual has received an inaugural Global Team Science Award from the Lupus Research Alliance.

The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.

Battling a deadly blood cancer, a New Jersey woman gets a second chance — thanks to precision medicine

Treatment with a ready-made preparation of human immune cells helps prevent infections in people whose immune systems are temporarily weakened by leukemia treatment.

Molecular characteristics detected in prostate cancers can provide clues that help predict how the disease will progress, according to new research from investigators at Weill Cornell Medicine and NewYork-Presbyterian.

A team led by investigators at Weill Cornell Medicine and NewYork-Presbyterian has used advanced technology and analytics to map, at single-cell resolution, the cellular landscape of diseased lung tissue in severe COVID-19 and other infectious lung diseases.